Innomicropharmaceuticals will announce MVR-T3011 U.S. clinical phase I intratumoral dosing data on 2021ASCO

Enomicropharmaceuticals announced that at the 2021 American Society of Clinical Oncology (ASCO) annual meeting to be opened on June 4-8, the company will announce the first clinical phase I results of intratumoral administration of MVR-T3011 products in a poster .

MVR-T3011 is the first new generation of recombinant herpes oncolytic virus (oHSV) independently developed by Innomicro.
It is a new viral backbone design based on the company's innovative and unique insights on oncolytic viruses and excellent genetic modification technology.

oHSV can selectively replicate and kill tumor cells without harming normal cells.

At the same time, the introduction of two foreign genes, PD-1 antibody and IL12, into MVR-T3011 also further strengthened the immune response.

This phase I clinical study was conducted at multiple sites in Australia and the United States, and subjects with advanced solid tumors were injected intratumorally with MVR-T3011 every other week.

The preliminary results of the clinical phase I study showed good safety.

MVR-T3011 was well tolerated at the test dose level, and there were no dose limiting toxicity (DLT) and treatment-related serious adverse events (SAEs) during the dose escalation phase of the study.

Analysis of biopsy samples of the subjects before and after treatment showed that tumor cells were significantly reduced and lymphocyte infiltration increased, indicating that the injection product caused a targeted anti-tumor response.

Most of the enrolled subjects are in stable condition, and their efficacy is under continuous evaluation.

At present, the dose escalation of the clinical phase I study of the MVR-T3011 intratumoral administration project at home and abroad has been completed, and the dose expansion phase is in progress.

Innomicro will continue to conduct in-depth research and development on its unique OvPENS platform, continuously expand new product pipelines, and strive to provide efficient, innovative and safe oncolytic virus treatment solutions for the anti-tumor market.

About Yinuowei Medicine Yinuowei Medicine is a biotechnology company dedicated to the development of a new generation of genetically modified herpes oncolytic viruses as cancer treatments.

Based on its OvPENS (OV+ Potent, Enabling, Novel & Safe) platform, the company has developed and constructed a complete set of scientific logic, R&D technology and production process to support the development and commercialization of oncolytic virus anti-tumor single drugs and combination drugs.

The OvPENS platform includes five modules: basic research, patented technology, genetic recombination technology, production technology, and commercial analysis, enabling the preclinical and clinical research and development of a new generation of oncolytic viruses with high efficiency, safety and innovation.